All News

Posters presented at the ATS 2021 International Conference noted some ways clinical characteristics associated with patients with chronic obstructive pulmonary disease (COPD) differ based on different demographics and smoking status.

Patients with sickle cell disease face substantial health care utilization and impaired health-related quality of life (HRQOL).

Because Medicaid has always been a shared program between federal and state governments, there has been wide variation in income limits. Today, 38 states and the District of Columbia have Medicaid expansion.

Injectable versions of HIV treatments and pre-exposure prophylaxis will be a game changer in terms of convenience over daily pills, noted Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health and director of the Center for Health, Identity, Behavior and Prevention Studies.

The latest coverage in the heart failure space from across MJH Life Sciences™.

A case of a patient with untreated psoriasis and nonischemic dilated cardiomyopathy (NIDCM) prompted clinicians to encourage study of the rare combination of disease.

Researchers say increase in immunotherapy was significant over the study period between 2016 and 2018.

Now that racial and ethnic disparities of atopic dermatitis prevalence among children have been confirmed, the next step in research will be to discover the reasons why those disparities exist, said Jonathan Silverberg, MD, PhD, MPH.

The World Health Organization’s Covax is feeling the strain from COVID-19 vaccine shortages; Argentina faces a new lockdown following a surge of COVID-19 cases; leronlimab ineffective against COVID-19.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

After switching to 1 of 2 adalimumab biosimilars, patients with inflammatory bowel disease (IBD) experienced comparable clinical outcomes to the reference product after 6 months, according to a recent study.

Joe Zein, MD, PhD, from Cleveland Clinic, explains factors apart from sex and age that can have an impact on a patient's asthma.

Confirmed disability progression is often used as a study endpoint to predict progression, but a new report says its predictive value may be overblown.

Matthew Reynolds, PhD, vice president of real-world evidence at IQVIA, discusses findings of a recent paper with the National Pharmaceutical Council on how COVID-19 affected real-world data and research, as well as implications for future studies.

An overview of the latest news in Parkinson disease reported across MJH Life Sciences™.

The new analysis suggests that dementia screenings might also include kidney function estimation.

As a validated health-related quality of life (HRQOL) measurement is not widely used among patients receiving this type of treatment, trials take advantage of traditional HRQOL tools.

HHS announces new mental health initiative; cervical cancer rates decline; 100 million Johnson & Johnson vaccine doses held up.

Results of a US claims database show erenumab is associated with reduced acute medication use and health care resource utilization.

Technological innovation is helping to reinvent the traditional health economics and outcomes research (HEOR) field as traditional and new players partner to leverage data sources.

Stakeholders identify the value elements of comprehensive genomic profiling (CGP) they find most important, as well as options for innovative contracts.

People who suffer from shift work sleep disorder face the highest risk of a car crash, although sleep apnea and insomnia also heighten a person’s risk.

The technique uses optical coherence tomography angiography to assess the motion of blood flow, instead of static images.

As the cost of therapies increases, US health plans are utilizing tools like step therapy, to ensure patients try cheaper alternatives first, and value assessment frameworks, to assist with the decision-making process.

Mark Trusheim, MS, BS, strategic director at the NEW Drug Development ParadIGmS program and visiting scientist at Massachusetts Institute of Technology, explains factors involved when considering whether a therapy would be suitable for performance-based contracting.

It is already known that dual-eligible older adults are at an increased risk for death in the year following a stay in the intensive care unit (ICU), but it previously wasn't known whether dual-eligible status is linked with functional decline after an ICU stay.